Cuny Thomas, Barlier Anne, Feelders Richard, Weryha Georges, Hofland Leo J, Ferone Diego, Gatto Federico
Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; CRN2M, UMR 7286 CNRS, Aix-Marseille University, 13344 Marseille cedex 15, France; Department of Endocrinology, University Hospital of Nancy Brabois, 54500 Vandœuvre-Les-Nancy, France.
CRN2M, UMR 7286 CNRS, Aix-Marseille University, 13344 Marseille cedex 15, France.
Ann Endocrinol (Paris). 2015 Feb;76(1):43-58. doi: 10.1016/j.ando.2014.10.002. Epub 2014 Nov 11.
Pituitary adenomas (PA) represent in the majority of cases, benign tumors whose treatment currently associate surgery, medical therapies and radiotherapy in a multidisciplinary approach. While trans-sphenoidal surgery remains, except for prolactin-secreting adenomas, the first-line treatment of PA, it can considerably be hampered by the existence of an invasive and/or aggressive tumor for which medical therapies are often requested. In this review, we extensively discuss, both at molecular and clinical levels, the medical therapies currently used and in development in the different phenotypes of pituitary adenomas.
垂体腺瘤（PA）在大多数情况下是良性肿瘤，目前其治疗采用多学科方法，包括手术、药物治疗和放射治疗。除泌乳素分泌型腺瘤外，经蝶窦手术仍是PA的一线治疗方法，但侵袭性和/或侵袭性肿瘤的存在可能会严重阻碍手术，对于这类肿瘤，通常需要药物治疗。在本综述中，我们在分子和临床层面广泛讨论了目前用于垂体腺瘤不同表型以及正在研发的药物治疗方法。
